Results suggested that CM1 improved hyperlipidemia through the downregulation of the plasma level of apolipoprotein B48, modulating the expression of certain significant genes and proteins in liver and suppressing preadipocyte differentiation in 3T3-L1 cells [100]. The gene discussed is APOB; the disease is hyperlipidemia.